Non-toxic polymer nanovectors for improved delivery of dexamethasone.

Benjamin Ede, Paraskevi (Vivian) Diamanti, David S Williams, Allison Blair*

*Corresponding author for this work

Research output: Contribution to journalArticle (Academic Journal)peer-review

2 Citations (Scopus)
42 Downloads (Pure)


Dexamethasone (Dex) is a highly insoluble front-line drug used in cancer therapy. Data from clinical trials indicates that the pharmacokinetics of Dex vary considerably between patients and prolonging drug exposure rather than increasing absolute dose may improve efficacy. Non-toxic, fully biodegradable Dex loaded nanovectors (NV) were formulated, via simple direct hydration within 10 min, as a vehicle to extend exposure and distribution in vivo. Dex-NV were just as effective as the free drug against primary human leukemia cells in vitro and in vivo. Importantly, high levels of DMSO solvent were not required in the NV formulations. Broad distribution of NV was seen rapidly following inoculation into mice. NV accumulated in major organs, including bone marrow and brain, known sanctuary sites for ALL. The study describes a non-toxic, more easily scalable system for improving Dex solubility for use in cancer and can be applied to other medical conditions associated with inflammation.
Original languageEnglish
Article number17263 (2021)
Number of pages7
JournalScientific Reports
Publication statusPublished - 26 Aug 2021


Dive into the research topics of 'Non-toxic polymer nanovectors for improved delivery of dexamethasone.'. Together they form a unique fingerprint.

Cite this